Kornimate/medical-research-clean huggingface dataset:
facial prediction technology for edentulous patients

Conditions: Edentulous Jaw

Summary: according to data from the world health organization, approximately 160 million people worldwide are edentulous. the incidence increases with age, and the proportion of edentulous patients is higher in the population aged 60 and above. loss of teeth or edentulism can affect facial appearance, causing people to feel self-conscious and loss confidence in social situations, and even lead to psychological illnesses. therefore, edentulous patients not only pay close attention to the recovery of oral function but also attach great importance to facial contour improvement. for a long time, due to technological limitations, clinicians have been unable to depict the changes in facial contour after implant placement for patients before surgery. however, with the development of artificial intelligence technology, deep learning-based methods for predicting soft tissue facial deformation have made this mission a possibility. this study established a multi-modal dataset for edentulous patients before and after implant restoration to lay the foundation for predicting facial contour changes after implant treatment. a graph generative adversarial network based on multi-modal data was proposed to achieve fast and high-precision facial contour prediction. to address the common challenges of slow computation and excessive computational resource consumption in current triangular mesh deformation simulation methods, this project innovatively proposed a graph generative adversarial network that uses multi-modal data and incorporates self-attention mechanisms to achieve fast and high-precision facial contour prediction for edentulous patients after implant restoration.


Eligibility criteria:
inclusion criteria: * patients with complete edentulism, * aged 50 years or above, * in good physical health, exclusion criteria: * patients who refuse to participate in the study， * patients who cannot undergo facial scanning.

Keywords: edentulous jaw deep learning oral implantology facial prediction
role of prophylaxis by oral fluid supplementation in prevention of postdural puncture headache

Conditions: Postdural Puncture Headache

Summary: postdural puncture headache (pdph) is defined, according to the international headache society, as any headache develops within 5 days after a lumbar puncture. it worsens within 15 minutes after sitting or standing and improves within 15 minutes after lying. for preventing pdph, there are some uncomfortable practices for patients (fluid supplementation and bed rest) and expensive for hospital (time spend for information and management of fluid intake). patients are usually advised by nurses. if "bed rest" is not effective in prevention of pdph, "fluid supplementation" is not an advice based on any evidence but only on routine. by this trial, the investigators want to evaluate the scientific value of this advice, in the standard patient care. the primary objective of this study is to compare oral hyperhydration (2 liters during 2 hours after lumbar puncture - the most common routine according to an internal pilot survey) versus no advice about the fluid intake to prevent the pdph. the second objective is to observe the day of apparition of pdph, between day 0 and day 5.

postdural puncture headache (pdph) is defined, according to the international headache society, as any headache develops within 5 days after a lumbar puncture. it worsens within 15 minutes after sitting or standing and improves within 15 minutes after lying. for preventing pdph, there are some uncomfortable practices for patients (fluid supplementation and bed rest) and expensive for hospital (time spend for information and management of fluid intake). patients are usually advised by nurses. if "bed rest" is not effective in prevention of pdph, "fluid supplementation" is not an advice based on any evidence but only on routine. by this trial, the investigators want to evaluate the scientific value of this advice by non-inferiority study, in the standard patient care. the primary objective of this study is to compare oral hyperhydration (2 liters during 2 hours after lumbar puncture - the most common routine according to an internal pilot survey) versus no advice about the fluid intake to prevent the pdph. it will be evaluated on the occurrence of pdph in both of the two groups the second objective is to observe the day of apparition of pdph, between day 0 and day 5.

Eligibility criteria:
inclusion criteria: * patient in need of dural puncture for diagnostic. * age between 18 and 60 years old. * patient willing to participate in the research. exclusion criteria: * pregnancy. * contraindication for increased oral fluid intake. * previous dural puncture within 5 day prior enrollment. * parenteral fluid intake superior at 266 ml for 2 hours after dural puncture (1000 ml per day). * enteral artificial feeding. * patient not in capacity to understand correctly french. * patient whose cannot be followed correctly by phone. * patient refusing to participate in the study.

Keywords: spinal puncture dural puncture nursing
an open-label extension study to evaluate long-term efficacy and safety of odevixibat in children with biliary atresia

Conditions: Biliary Atresia

Summary: an open-label extension study to evaluate long-term efficacy and safety of odevixibat (a4250) in children with biliary atresia

this is a phase 3, multi-center, open-label extension study to evaluate the long-term efficacy and safety of odevixibat in patients with biliary atresia (ba). patients who completed treatment in the a4250-011 bold study and meet eligibility criteria for study a4250-016 (bold-ext) can participate. the duration of the treatment period is 104 weeks, followed by a 4-week safety follow-up period. patients who wish to continue receiving odevixibat after 104 weeks can remain on treatment in the optional extension period (oep). up to 180 patients will be enrolled at approximately 70 sites in the north america, europe, the middle east and asia-pacific.

Eligibility criteria:
inclusion criteria: * completion of the 104-week treatment period of study a4250-011 * signed informed consent by caregiver exclusion criteria: * patients who were not compliant with study drug treatment or procedures in study a4250-011 as per the investigator's discretion * any conditions or abnormalities which, in the opinion of the investigator, may compromise the safety of the patient, or interfere with the patient participating in or completing the study * known hypersensitivity to any components of odevixibat * patients who are scheduled for a liver transplant or are likely to require a liver transplant in the immediate future based on the investigator's judgment
effects of aerobic exercise on skeletal muscle remodeling in colorectal cancer

Conditions: Colonic Neoplasms; Rectal Neoplasms

Summary: the goal of this clinical trial is to quantify the effects of aerobic exercise training compared to attention control on intermuscular adipose tissue in colorectal cancer survivors.


Eligibility criteria:
inclusion criteria: * age ≥18 years * histologically confirmed stage i, ii, or iii colon or rectal cancer * completed surgical resection with curative intent * completed other cancer-directed treatments * engage in \<150 minutes per week of moderate- to vigorous-intensity structured endurance exercise * no planned major surgery during the study period * readiness to exercise, as determined by a modified version of the physical activity readiness questionnaire * ability to provide written informed consent * provide written approval by a qualified healthcare professional * willing to be randomized exclusion criteria: * evidence of metastatic or recurrent colorectal cancer * concurrently actively treated other (non-colorectal) cancer * scheduled to receive other postoperative cancer-directed treatment(s) * currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks * currently participating in another study with competing outcomes * contraindications to magnetic resonance imaging * any dietary condition or restriction that would limit tolerance of a mixed meal challenge * any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, or other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol * any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol
self-efficacy and well-being of patients with fibrotic interstitial lung disease

Conditions: Interstitial Lung Disease; Fibrotic Lung Disease; Self Efficacy; Self-management; Patient Education; Quality of Life

Summary: patients with fibrotic insterstitial lung disease (ild) participating in inpatient rehabilitation or in outpatient pulmonary care will be invited to participate in this observational study. patients will fill out questionnaire regarding quality of life and symptoms at baseline and follow-up (at the end of rehabilitation or after the second outpatient ild consultation). additionally, clinical data obtained in clinical routine or for the iip registry will be used for this project. the aim is to assess changes in self-efficacy and quality of life over time and to establish a control cohort for a later feasibility study on a educational and self-management intervention (currently in planning).


Eligibility criteria:
inclusion criteria are: * for berner reha zentrum only: diagnosis of a fild as major indication for pulmonary rehabilitation * for inselspital only: enrolled in idiopathic interstitial pneumonia (iip) cohort study (nr. 246/15 / pb_2016-01524) and agreed to further use of data for further research purpose * age ≥ 18 years * written informed consent exclusion criteria are: * cognitive inability or insufficient knowledge of project language (german) to follow informed consent or study procedures * sarcoidosis

Keywords: self efficacy self-management patient education well-beeing quality of life fibrotic lung disease interstitial lung disease
the diagnostic yield and safety of transbronchial cryobiopsy in diffuse parenchymal lung diseases

Conditions: Diffuse Parenchymal Lung Diseases

Summary: the diagnostic yield and safety of transbronchial cryobiopsy in the diagnosis of diffuse parenchymal lung diseases are investigated in this multicenter, prospective and real world study.


Eligibility criteria:
inclusion criteria: 1. the patients are admitted in the institution as dpld, while undefined after thorough history collection, laboratory examination and radiological data. 2. transbronchial cryobiopsy(tbcb) is indicated by clinicians for definitive diagnosis and patients are content with the examination with agreement signed. 3. blood gas analysis, routine blood test, ecg examination, coagulation function, immunological examination, chest hrct, and liver/kidney function test have been completed. exclusion criteria: 1. the radiological data indicates non-dpld 2. the clinical examinations mentioned above are not completed. 3. the patient cannot endure or does not agree the procedure.

Keywords: transbrochial cryobiopsy diffuse parenchymal lung diseases diagnosis
primary pci in patients with st-elevation myocardial infarction and multivessel disease: treatment of culprit lesion only or complete revascularization

Conditions: ST-elevation Myocardial Infarction; Multi Vessel Disease

Summary: in patients with st-elevation myocardial infarction (stemi) the primary treatment is acute angioplasty of the acute occlusion (culprit lesion). in stemi patients with multi vessel disease (mvd) no evidence based treatment of the non-culprit lesions exists. we aim to provide evidence as to whether full revascularization or revascularization of the culprit lesion only provides the best prognosis for the patient.

stemi patients with mvd (30% of total stemi population) are - following successful primary angioplasty - randomized to either no additional percutaneous coronary intervention (pci) of other lesions or full revascularisation guided by fractional flow reserve (ffr). eligible coronary arteries must be \>2.0 mm in diameter and at the discretion of the operator suitable for pci. only arteries with angiographically stenoses \> 50% can be randomized. all randomized lesions with diameter stenosis \> 50% and \ 90% are treated without prior ffr. full revascularization is a priori obtained by means of pci. if, however, pci is considered inferior to coronary artery bypass grafting the latter option can be chosen.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * acute onset of chest pain of \< 12 hours' duration. * st-segment elevation ≥ 0.1 millivolt in ≥ 2 contiguous leads, signs of a true posterior infarction or documented newly developed left bundle branch block. * culprit lesion in a major native vessel. * mvd (non-culprit vessels with angiographic stenosis \>50%) * successful primary pci exclusion criteria: * pregnancy. * known intolerance of acetylsalicylic acid, clopidogrel, heparin or contrast. * inability to understand information or to provide informed consent. * haemorrhagic diathesis or known coagulopathy. * stent thrombosis * significant left main stem stenosis * cardiogenic shock at admittance

Keywords: stemi mvd full revascularization culprit lesion revascularization only primary pci
outcome following hylan f- 20 (synvisc) + corticosteroid injections for the treatment of osteoarthritis of the knee

Conditions: Osteoarthritis, Knee

Summary: the goal of viscosupplementation is to replenish synovial fluid, which will improve patient symptoms and mobility. viscosupplementation of the knee with hyaluronic acid injections has been shown to improve symptoms in patients with osteoarthritis. recent studies have shown that this improvement may be highly variable based on the time from treatment, especially in the first 12 weeks following treatment. the purpose of this study is to document the outcomes following a treatment protocol in which corticosteroid is used in addition to the initial synvisc injection in the series of three injections.

upon initial visit, all study patients will complete an informed consent. after consent, patients will complete the baseline questionnaire packet, which includes a questionnaire with several validated scoring systems. following injection, patients will receive a diary to document any adverse events between the first and second injection. in one week, patients will return for a second visit to receive the second injection. again they will be asked to maintain their diary of adverse events following the second injection. the patient will then receive the final injection at week 3 and will again complete a diary of events for one week. at 1 week, 3 weeks, 6 weeks, 12 weeks, and 26 weeks following the completed series of injections, the patients will complete a form that will include the pain, stiffness, and physical function subscales of the womac score and a 10 point patient satisfaction question. at 6 months, the patients will receive by mail the same questionnaire packet they received at baseline, with the addition of patient satisfaction and subsequent injury/treatment questions.

Eligibility criteria:
inclusion criteria: * men or women aged 18 to 80 years * with a diagnosis of osteoarthritis of the knee. diagnosis will be based on radiographic examination (kellgren-lawrence 2 or 3) or by previous arthroscopic diagnosis. surgical treatment for osteoarthritis will be limited to arthroscopic surgeries that include removal of loose bodies, resection of unstable meniscus tears and loose or unstable chondral flaps, removal of osteophytes if they limit extension, and lysis of adhesions. these types of treatments may provide symptomatic relief by increasing joint volume in knees with osteoarthritis and relieving joint contact pressures. exclusion criteria: * patients with grade 4 kellgren-lawrence on radiographic examination will be excluded. * patients with a prior synovectomy on knee to be injected will be excluded. * patients will be excluded if they have rheumatoid disease or any other serious systemic disease, acute synovitis or excessive effusion, allergy to avian products/hyaluronan-based injection components/corticosteroid injection, pregnant, previous arthroscopic surgery within the last 6 months or had a joint infection within the previous 3 months. * patients who have undergone a prior synovectomy will not be included.

Keywords: knee injection function osteoarthritis
trk-820 study in subjects on hemodialysis with or without uremic pruritus

Conditions: Uremic Pruritus

Summary: this study is a 2-part study. part a is a single-dose, open-label study design to determine the pk, safety and tolerability of 5 μg trk-820 oral administration in subjects with end-stage renal disease (esrd) who require hemodialysis. part b is a multiple dose, open-label study design to determine the pk, pd, safety and tolerability of multiple doses in subjects with esrd who require hemodialysis with refractory uremic pruritus (up). each subject will receive 3 doses of trk-820 (2.5, 5 and 10 μg).


Eligibility criteria:
inclusion criteria: * adult non-smoking male and female subjects (≥ 18 years of age) who have esrd requiring hemodialysis, at least 3 times a week. * subjects has a clinical diagnosis of up, which is uncontrolled by current medications or treatments.(part b only) exclusion criteria: * subject has a known hypersensitivity to opioids or the ingredients of the study medication. * subject has pruritus other than related to esrd (i.e., up).(part b only)

Keywords: trk-820 hemodialysis uremic pruritus
sgi-110 in the treatment of advanced hepatocellular carcinoma (hcc)

Conditions: Hepatocellular Carcinoma

Summary: a phase 2 open-label, single-arm, non-randomized study in the treatment of advanced hepatocellular carcinoma (hcc) patients who failed prior treatment with sorafenib using a simon's 2-stage design. a set minimum number of patients must demonstrate disease control at 16 weeks to proceed to stage 2. at stage 2, a set number of patients must have disease control at 16 weeks to declare that sgi-110 is of interest in the treatment of advanced hcc after failure of prior sorafenib.


Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. histological or cytological confirmed hepatocellular carcinoma with advanced stage disease 3. received prior sorafenib treatment, and showed evidence of disease progression, which is defined as investigator verified radiologic progression, or intolerance of prior systemic therapy, which is defined as having had clinically significant adverse events that persisted despite one or more dose reductions or interruptions 4. eastern cooperative oncology group (ecog) performance status of 0-1 5. acceptable organ function 6. signed an approved informed consent exclusion criteria: 1. known hypersensitivity to sgi-110 2. adequate washout of prior radiation, chemotherapy or other locoregional therapy 3. abnormal left ventricular ejection fraction 4. uncontrolled ischemic heart disease or a history of congestive cardiac failure 5. known brain metastases 6. clinically evident ascites 7. child-pugh c cirrhosis or child-pugh b cirrhosis with more than 7 points 8. prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, non-metastatic prostate cancer with normal prostate-specific antigen (psa) or other cancer from which the subject has been disease free for at least three years 9. known history of human immunodeficiency virus (hiv)
evaluation of effect of cryoballoon focal ablation system on human esophageal epithelium

Conditions: Barrett's Esophagus; Esophageal Squamous Dysplasia; Esophageal Cancer

Summary: assess cryoablation (cryoballoon ablation cryotherapy) for treatment of dysplastic barrett's esophagus, esophageal squamous dysplasia and early esophageal cancer. the cryoablation treatment will be offered as an alternative to standard ablation therapies such as radiofrequency ablation, argon plasma coagulation and carbon dioxide cryotherapy).

cryoablation (cryotherapy) is an established type of mucosal ablation for treatment of various conditions in the gi tract, including barrett's esophagus and esophageal cancer. the purpose of this study is to assess the safety, feasibility and performance of cryoablation system (the c2 focal cryoablation device in patients with be and esophageal squamous dysplasia who need ablation therapy for clinical standard care. the new cryoablation treatment will be offered as an alternative to standard ablation therapies already in place (radiofrequency ablation, carbon dioxide cryotherapy).

Eligibility criteria:
inclusion criteria: * patients recommended for ablation of either barrett's esophagus with dysplasia or esophageal squamous dysplasia, scheduled for upper endoscopy. exclusion criteria: * patient unable to undergo endoscopy, * patients with visible esophageal mass.

Keywords: barrett's esophagus with dysplasia early esophageal cancer
effects of coseal on bleeding & adhesions in pediatric heart surgery

Conditions: Congenital Heart Defect; Surgery-Induced Tissue Adhesions; Hemorrhage

Summary: this is a prospective, randomized, open-label, blinded-evaluator study that will evaluate the effectiveness of a surgical sealant (coseal) composed of biocompatible polyethylene glycol on the formation of mediastinal and pericardial adhesions in children undergoing staged surgical reconstruction (potential procedures include: blalock-taussig type operation, classical glenn procedure, bidirectional glenn procedure, norwood). additionally, bleeding will be evaluated by drainage post-operatively through surgical site drainage output.


Eligibility criteria:
inclusion criteria: * have an acceptable surrogate capable of giving consent on the subject's behalf. * pediatric patients ages 0 - 17 * have a cardiac disease which requires staged cardiac surgery and resternotomy * non-emergent state or emergent state with sufficient time to educate and consent exclusion criteria: * an immune system disorder * unplanned reoperation * known hypersensitivity to components in coseal * patients undergoing reoperation less than 3 months after the primary surgery
studying the effectiveness of early invasive treatment in elderly patients with high-risk non-st-segment elevation acute coronary syndrome.

Conditions: Myocardial Infarction

Summary: the goal of this is observational study is to compare about mace events and predisposing factors related to mace events in elderly patients with high-risk non-st acute coronary syndromes receiving early versus late invasive treatment . this study will anwser two questions. question 1: what will factors associate with implementing a late invasive strategy in elderly patients with high-risk non-st-segment elevation acute coronary syndrome ? question 2: is a meaningful difference about mortality and complication rates as re-myocardial infarction, heart failure, re-hospitalization, stroke after 12 months between two groups of patients undergoing early invasive and late invasive strategies in elderly patients with in high-risk non-st-segment elevation acute coronary syndrome?


Eligibility criteria:
inclusion criteria: * aged 60 years and older * high - risk non-st-segment elevation acute coronary syndrome (according to the 2023 european heart association recommended standards). * receives reperfusion intervention. exclusion criteria: * acute coronary syndrome due to stent thrombosis, or coronary artery bypass graft occlusion. * incomplete medical records.

Keywords: percutaneous coronary intervention, elderly, non-st-segment elevation